Pharmaceutical co-development services

Protagen specializes in Pharma development services in the fields of immuno-oncology and autoimmune disease. Via co-development projects with its strategic partners, Protagen enables effective, targeted immuno-therapeutic development for improved patient care.

Protagen is a lab services business that is at the forefront of immuno-profiling and the discovery of novel biomarkers for immuno-oncology, autoimmune disease, and other immune-driven diseases. Using its proprietary immuno-profiling platform (SeroTag®), and stratification arrays based on biomarker panels (NavigAID) to screen patient serum specimens, Protagen is able to provide:

  • Better disease activity assessment
  • Improved response prediction
  • Patient monitoring
  • The early detection of immune-related adverse events (irAEs)

Find out why Protagen is engaged by 5 of the top 10 pharma.


While immunotherapies such as therapeutic vaccination and checkpoint inhibition hold great promise for treating cancer, they currently only work effectively on a small subset of patients. In addition, as they stimulate the immune system to target the body’s own cells, they can also trigger irAEs and even the onset of autoimmune disease.


NavigAID SLE separates and defines subgroups in Systemic Lupus Erythematosus (SLE), overcoming heterogeneity and enabling new approaches to successful drug development.

NavigAID SSc

NavigAID SSc is a new disease stratification array which separates and defines disease specific subgroup via the simple measurement of serum biomarkers.

SeroTag platform and NavigAID pipeline

Protagen is uniquely positioned to synergistically combine the largest global human protein libraries with high-throughput identification of disease and treatment markers in patient samples (SeroTag to develop diagnostics and companion diagnostics.